{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T17:28:35.962185",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "disease-free survival",
        "long-term survival",
        "prolonged survival",
        "improved survival",
        "improved prognosis",
        "survival",
        "time to death",
        "treatment-related mortality",
        "perioperative mortality",
        "mortality not related to hepatocellular carcinoma"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; mRECIST)",
        "objective response rate (ORR; RECIST 1.1)",
        "tumor response rate",
        "tumour response",
        "tumour response to locoregional therapy",
        "radiologic response",
        "pathological response",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "complete response (CR)",
        "complete response (mRECIST)",
        "partial response (PR)",
        "partial response (mRECIST)",
        "minor response (reduction of tumour size by 25 to 50%)",
        "objective tumour response",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "stable disease (SD; defined as stable disease lasting for at least 4 weeks)",
        "stable disease (for at least 16 weeks)",
        "tumor reduction",
        "tumour size",
        "tumour necrosis",
        "local control",
        "local tumor control",
        "local tumour control",
        "bridge to transplant",
        "bridging to transplantation",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging)",
        "malignant transformation",
        "early detection of recurrence",
        "recurrence",
        "recurrence rate",
        "disease recurrence",
        "local recurrence",
        "reduction of progression",
        "best supportive therapy"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (PFS; mRECIST)",
        "progression-free survival (RECIST 1.1)",
        "time to progression (TTP)",
        "time to progression",
        "time to tumour progression",
        "time to progression of the tumor",
        "time to radiological disease progression",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression (TTSP)",
        "time to symptom progression",
        "time to symptom development",
        "disease progression",
        "time to response",
        "duration of response (DoR)",
        "time-to-progression",
        "time-to-symptom worsening (TSW; EORTC QLQ-C30 domains)",
        "time-to-symptom worsening (TSW; EORTC QLQ-HCC18 domains)",
        "time-to-symptom worsening (TSW; EQ-5D VAS)",
        "time-to-symptom worsening (TSW; EQ-5D HUI)",
        "time to deterioration"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (CTCAE v5.0)",
        "adverse reactions (general)",
        "adverse reactions leading to discontinuation of treatment",
        "adverse events leading to discontinuation",
        "adverse events (grade 3 and higher)",
        "grade 3 and 4 adverse reactions",
        "grade 3 adverse reactions",
        "grade 5 adverse events",
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "severe adverse events",
        "serious complications",
        "complication incidence",
        "complications",
        "post-treatment complications",
        "long-term treatment-related complications",
        "treatment-related deaths",
        "dropout rate for critical toxicity",
        "drop-out rate",
        "treatment-related mortality",
        "infections",
        "liver failure",
        "hepatic failure",
        "irreversible liver failure",
        "hepatic impairment",
        "hepatic insufficiency",
        "marked impairment of hepatic function",
        "liver injury",
        "liver disorders",
        "biliary injury",
        "portal vein thrombosis",
        "hepatic arterial thrombosis",
        "haemorrhage",
        "bleeding",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "gastrointestinal bleeding",
        "haemorrhagic events",
        "cardiac ischaemia",
        "myocardial ischaemia",
        "myocardial infarction",
        "cardiac infarction",
        "cerebral vascular accident",
        "congestive heart failure",
        "hypertension",
        "arterial hypertension",
        "grade 3-4 hypertension",
        "hypertension (grade 3/4)",
        "arterial thromboembolic events",
        "renal events",
        "renal failure",
        "proteinuria",
        "grade 3-4 proteinuria",
        "increased bilirubin",
        "increased serum bilirubin",
        "grade 3-4 increased serum bilirubin",
        "increased alanine aminotransferase (ALT)",
        "grade 3-4 increased alanine aminotransferase (ALT)",
        "increased aspartate aminotransferase (AST)",
        "grade 3-4 increased aspartate aminotransferase (AST)",
        "transient increase in transaminases",
        "increased amylase",
        "increased lipase",
        "infusion reactions",
        "grade 3-4 infusion reaction",
        "immuno-mediated hepatitis",
        "hepatic encephalopathy",
        "encephalopathies",
        "intestinal failure",
        "wound healing complications",
        "postoperative softening",
        "gastrointestinal perforation",
        "mucosal inflammation",
        "stomatitis",
        "dyspepsia",
        "dysphagia",
        "gastro oesophageal reflux disease",
        "constipation",
        "vomiting",
        "nausea",
        "grade 3-4 nausea",
        "diarrhoea",
        "diarrhoea (grade 3/4)",
        "grade 3-4 diarrhoea",
        "diarrhoea (EORTC QLQ-C30 domain)",
        "anorexia",
        "loss of appetite",
        "decreased appetite",
        "grade 3-4 decreased appetite",
        "weight loss",
        "decreased weight",
        "grade 3-4 weight loss",
        "fatigue",
        "grade 3-4 fatigue",
        "asthenia",
        "grade 3-4 asthenia",
        "pain",
        "abdominal pain",
        "abdominal pain (grade 3/4)",
        "grade 3-4 abdominal pain",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "headache",
        "cough",
        "dyspnoea",
        "shortness of breath",
        "fever",
        "grade 3-4 fever",
        "influenza like illness",
        "rash",
        "palmar rash",
        "skin rash or desquamation",
        "rash or skin desquamation (grade 3 or 4)",
        "skin desquamation",
        "dermatological toxicities",
        "pruritus",
        "erythema",
        "dry skin",
        "alopecia",
        "folliculitis",
        "acne",
        "dermatitis exfoliative",
        "hyperkeratosis",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand-foot skin reaction (grade 3 or 4)",
        "hand feeding reactions (grade 3/4)",
        "skin rash",
        "skin rash or desquamation",
        "lymphoedema (grade 3/4)",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "grade 3-4 thrombocytopenia",
        "hypophosphataemia",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "depression",
        "anxiety",
        "stress",
        "peripheral sensory neuropathy",
        "dysgeusia",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "dysphonia",
        "epilepsy",
        "erectile dysfunction",
        "increased carcinogenicity",
        "metastasis",
        "sudden death",
        "morbidity",
        "serious complications",
        "complication rate",
        "intraoperative complications",
        "admission",
        "frequency of hospitalisation",
        "length of hospital stay (LOS)",
        "length of admission",
        "need for hospital medical day (HDM)",
        "intrahospital administration",
        "outpatient regimen",
        "ambulatory regimen",
        "utilization of resources",
        "resource use"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "severe adverse events",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality"
      ],
      "discontinuations": [
        "adverse reactions leading to discontinuation of treatment",
        "adverse events leading to discontinuation",
        "dropout rate for critical toxicity",
        "drop-out rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "quality of life",
        "health-related quality of life (HRQoL)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "health status",
        "validated and reliable instrument for overall quality of life",
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (VAS)",
        "EQ-5D health utility index (HUI)",
        "EQ VAS (Euro QoL visual analogue scale)",
        "SF-36",
        "FACT-G (Functional Assessment of Cancer Therapy â€“ General)",
        "Functional Assessment of Cancer Therapy (FACT-G)",
        "Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)",
        "NRS Symptomatic Rating Scale",
        "FHSI-8 questionnaire",
        "visual analogue scale"
      ],
      "functional_status": [
        "body image (EORTC QLQ-HCC18 functional scale)",
        "nutrition (EORTC QLQ-HCC18 functional scale)",
        "sex life (EORTC QLQ-HCC18 functional scale)",
        "cognitive functioning (health-related quality of life dimension)",
        "role functioning",
        "pain (EORTC QLQ-C30 domain)",
        "nutrition (EORTC QLQ-HCC18 domain)",
        "body image (EORTC QLQ-HCC18 domain)"
      ],
      "symptom_measures": [
        "time to symptom progression (TTSP)",
        "time to symptom progression",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time-to-symptom worsening (TSW; EORTC QLQ-C30 domains)",
        "time-to-symptom worsening (TSW; EORTC QLQ-HCC18 domains)",
        "time-to-symptom worsening (TSW; EQ-5D VAS)",
        "time-to-symptom worsening (TSW; EQ-5D HUI)",
        "pain",
        "diarrhoea (EORTC QLQ-C30 domain)",
        "cancer-related fatigue",
        "distress (physical and psychological complaints)",
        "depression",
        "anxiety",
        "stress"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness",
        "quality-adjusted life years (QALYs)",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ],
      "utilities": [
        "EQ-5D health utility index (HUI)",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (VAS)",
        "EQ VAS (Euro QoL visual analogue scale)"
      ],
      "resource_utilization": [
        "resource use",
        "utilization of resources",
        "admission",
        "frequency of hospitalisation",
        "length of hospital stay (LOS)",
        "length of admission",
        "need for hospital medical day (HDM)",
        "intrahospital administration",
        "outpatient regimen",
        "ambulatory regimen",
        "days of missed work"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "prognosis (BCLC staging system)",
        "prognosis assessment (CLIP, BCLC)",
        "therapeutic efficacy",
        "detection of early hepatocellular carcinoma",
        "monitoring by CT scan",
        "monitoring by MRI scan",
        "pathology report (tumour type, WHO degree of differentiation, distance to resection edges, capsule invasion, carinvasion, tumour size, tumour number, satellites, effect of ablative or neoadjuvant therapy as estimated percentage of vital tumour tissue, lymphoid involvement, background liver including pre-malignant changes)",
        "histological and prognostic parameters (pathomorphological evaluation)",
        "genetic subtypes identification",
        "tumour seeding",
        "tumour recurrence",
        "early detection of recurrence",
        "alpha-fetoprotein (AFP) for detection of recurrence",
        "best supportive therapy"
      ],
      "biomarkers": [
        "plasma pharmacokinetics parameters",
        "pharmacokinetics/pharmacodynamics (PK/PD) relationship",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "vital signs",
        "electrocardiography",
        "tumour markers"
      ]
    }
  }
}